Trial Profile

Phase II study of personalized titration of axitinib using therapeutic drug monitoring (TDM) in sunitinib-refractory metastatic or advanced renal cell carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

27 Sep 2018 Status changed from active, no longer recruiting to completed.
18 Feb 2017 Primary endpoint (Progression-free survival rate) has been met.
18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com